Stock AnalizNational Health Investors Inc. NHI
Real Estate Investment Trusts · data as of November 13, 2026
National Health Investors Inc. (NHI) is a real estate company listed in the US with a market value of about $3.1B. In the twelve months to September 30, 2026 it had revenue of $456M and net income of $697M, a net margin of 153.0%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 4.4, a price to free cash flow of 13.2, 5-year revenue growth of 2% a year. A discounted cash flow model with moderate assumptions puts its intrinsic value about 31% above the current price.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $456M | $376M | $335M | $320M | $278M | $299M | $333M | $318M | $295M | $279M | $248M |
| Net income | $697M | $142M | $138M | $136M | $66M | $112M | $185M | $160M | $154M | $159M | $152M |
| Free cash flow | $234M | -$57M | $50M | $135M | $174M | $161M | $115M | $4M | $60M | $22M | -$218M |
| EPS (diluted) | $14.24 | $3.02 | $3.13 | $3.13 | $1.48 | $2.44 | $4.14 | $3.67 | $3.67 | $3.87 | $3.87 |
| Net margin | 153.0% | 37.9% | 41.2% | 42.4% | 23.9% | 37.4% | 55.6% | 50.4% | 52.4% | 57.2% | 61.0% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $74.25, 18% above the current price; targets range from $65.00 to $88.00; the consensus rating is “Buy”; expected EPS is $14.09 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is National Health Investors’s P/E ratio?
About 4.4, based on the last twelve months of diluted earnings per share (forward P/E about 10.0).
Is National Health Investors stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 31% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does National Health Investors pay a dividend?
Yes. The dividend yield is about 5.97%, and it has paid dividends for 10 years in our data.
Is National Health Investors a good stock to buy?
We do not give buy or sell advice. National Health Investors scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.